Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.

Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM.

J Thorac Oncol. 2019 Aug 22. pii: S1556-0864(19)30665-3. doi: 10.1016/j.jtho.2019.08.003. [Epub ahead of print]

PMID:
31446141
2.

SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).

Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS.

J Thorac Oncol. 2019 Oct;14(10):1853-1859. doi: 10.1016/j.jtho.2019.06.027. Epub 2019 Jul 11.

PMID:
31302234
3.

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.

Devarakonda S, Sankararaman S, Herzog BH, Gold KA, Waqar SN, Ward JP, Raymond VM, Lanman RB, Chaudhuri AA, Owonikoko TK, Li BT, Poirier JT, Rudin CM, Govindan R, Morgensztern D.

Clin Cancer Res. 2019 Oct 15;25(20):6119-6126. doi: 10.1158/1078-0432.CCR-19-0879. Epub 2019 Jul 12.

PMID:
31300452
4.

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.

Morgensztern D, Rose M, Waqar SN, Morris J, Ma PC, Reid T, Brzezniak CE, Zeman KG, Padmanabhan A, Hirth J, I Spira A, Trepel JB, Padda SK.

Br J Cancer. 2019 Jul;121(3):211-217. doi: 10.1038/s41416-019-0504-8. Epub 2019 Jun 24.

PMID:
31231122
5.

Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy.

Morgensztern D, Ko A, O'Brien M, Ong TJ, Waqar SN, Socinski MA, Postmus PE, Bhore R.

Cancer. 2019 Jul 15;125(14):2394-2399. doi: 10.1002/cncr.32114. Epub 2019 Apr 1.

PMID:
30933354
6.

Lorlatinib: a new-generation drug for ALK-positive NSCLC.

Waqar SN, Morgensztern D.

Lancet Oncol. 2018 Dec;19(12):1555-1557. doi: 10.1016/S1470-2045(18)30789-7. Epub 2018 Nov 6. No abstract available.

PMID:
30413381
7.

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer.

Wagner AH, Devarakonda S, Skidmore ZL, Krysiak K, Ramu A, Trani L, Kunisaki J, Masood A, Waqar SN, Spies NC, Morgensztern D, Waligorski J, Ponce J, Fulton RS, Maggi LB Jr, Weber JD, Watson MA, O'Conor CJ, Ritter JH, Olsen RR, Cheng H, Mukhopadhyay A, Can I, Cessna MH, Oliver TG, Mardis ER, Wilson RK, Griffith M, Griffith OL, Govindan R.

Nat Commun. 2018 Sep 17;9(1):3787. doi: 10.1038/s41467-018-06162-9.

8.

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.

Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA.

J Clin Oncol. 2018 Aug 10;36(23):2386-2394. doi: 10.1200/JCO.2018.77.7672. Epub 2018 Jun 15.

9.

A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.

Giaccone G, Sanborn RE, Waqar SN, Martinez-Marti A, Ponce S, Zhen H, Kennealey G, Erickson-Viitanen S, Schaefer E.

Clin Lung Cancer. 2018 Sep;19(5):e567-e574. doi: 10.1016/j.cllc.2018.03.016. Epub 2018 Mar 23.

PMID:
29681434
10.

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.

McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC.

Clin Cancer Res. 2018 Jun 15;24(12):2758-2770. doi: 10.1158/1078-0432.CCR-17-2588. Epub 2018 Mar 29.

11.

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.

Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA.

Clin Cancer Res. 2018 Jun 15;24(12):2771-2779. doi: 10.1158/1078-0432.CCR-17-2398. Epub 2018 Mar 21.

12.

Non-small-cell Lung Cancer With Brain Metastasis at Presentation.

Waqar SN, Samson PP, Robinson CG, Bradley J, Devarakonda S, Du L, Govindan R, Gao F, Puri V, Morgensztern D.

Clin Lung Cancer. 2018 Jul;19(4):e373-e379. doi: 10.1016/j.cllc.2018.01.007. Epub 2018 Mar 9.

PMID:
29526531
13.

Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small Cell Lung Cancer.

Morgensztern D, Samson PS, Waqar SN, Devarakonda S, Robinson CG, Govindan R, Puri V.

J Thorac Oncol. 2018 Apr;13(4):543-549. doi: 10.1016/j.jtho.2018.01.010. Epub 2018 Feb 2.

14.

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).

Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators.

Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. doi: 10.1158/1078-0432.CCR-17-2289. Epub 2017 Dec 7.

15.

Percutaneous Image-Guided Ablation in the Treatment of Osseous Metastases from Non-small Cell Lung Cancer.

Ma Y, Wallace AN, Waqar SN, Morgensztern D, Madaelil TP, Tomasian A, Jennings JW.

Cardiovasc Intervent Radiol. 2018 May;41(5):726-733. doi: 10.1007/s00270-017-1843-6. Epub 2017 Dec 4.

PMID:
29204695
16.

A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients.

Byers LA, Horn L, Ghandi J, Kloecker G, Owonikoko T, Waqar SN, Krzakowski M, Cardnell RJ, Fujimoto J, Taverna P, Azab M, Camidge DR.

Oncotarget. 2017 Aug 3;8(46):81441-81454. doi: 10.18632/oncotarget.19888. eCollection 2017 Oct 6.

17.

Treatment advances in small cell lung cancer (SCLC).

Waqar SN, Morgensztern D.

Pharmacol Ther. 2017 Dec;180:16-23. doi: 10.1016/j.pharmthera.2017.06.002. Epub 2017 Jun 1. Review.

PMID:
28579387
18.

Precision medicine in lung cancer: the battle continues.

Waqar SN, Morgensztern D.

J Thorac Dis. 2016 Nov;8(11):2991-2993. doi: 10.21037/jtd.2016.11.46. No abstract available.

19.

Systemic Treatment of Brain Metastases.

Waqar SN, Morgensztern D, Govindan R.

Hematol Oncol Clin North Am. 2017 Feb;31(1):157-176. doi: 10.1016/j.hoc.2016.08.007. Review.

PMID:
27912831
20.

Immune checkpoint inhibition in patients with brain metastases.

Johanns T, Waqar SN, Morgensztern D.

Ann Transl Med. 2016 Oct;4(Suppl 1):S9. No abstract available.

21.

Role for adjuvant chemotherapy in patients with resected small cell lung cancer.

Du L, Waqar SN, Morgensztern D.

J Thorac Dis. 2016 Aug;8(8):1891-2. doi: 10.21037/jtd.2016.07.15. No abstract available.

22.

Multimodality Therapy for NSCLC.

Du L, Waqar SN, Morgensztern D.

Cancer Treat Res. 2016;170:151-63. doi: 10.1007/978-3-319-40389-2_7. Review.

PMID:
27535393
23.

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM.

J Thorac Oncol. 2016 Sep;11(9):1387-96. doi: 10.1016/j.jtho.2016.05.009. Epub 2016 Jul 9. Review.

24.

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC.

Morgensztern D, Du L, Waqar SN, Patel A, Samson P, Devarakonda S, Gao F, Robinson CG, Bradley J, Baggstrom M, Masood A, Govindan R, Puri V.

J Thorac Oncol. 2016 Oct;11(10):1729-35. doi: 10.1016/j.jtho.2016.05.022. Epub 2016 Jun 8.

25.

Delayed nausea and vomiting from carboplatin doublet chemotherapy.

Waqar SN, Mann J, Baggstrom MQ, Waqar MA, Chitneni P, Williams K, Gao F, Morgensztern D, Govindan R.

Acta Oncol. 2016 Jun;55(6):700-4. doi: 10.3109/0284186X.2016.1154603. Epub 2016 May 4.

26.

A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer.

Waqar SN, Baggstrom MQ, Morgensztern D, Williams K, Rigden C, Govindan R.

Chemotherapy. 2016;61(3):144-7. doi: 10.1159/000442147. Epub 2016 Jan 19.

27.

Immunogenicity of Influenza Vaccination in Patients With Cancer.

Waqar SN, Boehmer L, Morgensztern D, Wang-Gillam A, Sorscher S, Lawrence S, Gao F, Guebert K, Williams K, Govindan R.

Am J Clin Oncol. 2018 Mar;41(3):248-253. doi: 10.1097/COC.0000000000000257.

28.

Brain Metastases at Presentation in Patients With Non-Small Cell Lung Cancer.

Waqar SN, Waqar SH, Trinkaus K, Gadea CA, Robinson CG, Bradley J, Watson MA, Puri V, Govindan R, Morgensztern D.

Am J Clin Oncol. 2018 Jan;41(1):36-40. doi: 10.1097/COC.0000000000000230.

29.

Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?

Waqar SN, Morgensztern D.

Expert Rev Clin Immunol. 2015;11(8):871-3. doi: 10.1586/1744666X.2015.1054374. Epub 2015 Jun 7. Review.

PMID:
26051156
30.

MET Mutation Associated with Responsiveness to Crizotinib.

Waqar SN, Morgensztern D, Sehn J.

J Thorac Oncol. 2015 May;10(5):e29-31. doi: 10.1097/JTO.0000000000000478. No abstract available.

31.

Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base.

Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, Baggstrom MQ, Govindan R, Bell JM, Guthrie TJ, Colditz GA, Crabtree TD, Kreisel D, Krupnick AS, Patterson GA, Meyers BF, Puri V.

J Clin Oncol. 2015 Mar 10;33(8):870-6. doi: 10.1200/JCO.2014.58.5380. Epub 2015 Feb 9.

32.

Clinical next-generation sequencing in patients with non-small cell lung cancer.

Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT, Duncavage EJ, Cottrell CE, Kulkarni S, Nagarajan R, Seibert K, Baggstrom M, Waqar SN, Pfeifer JD, Morgensztern D, Govindan R.

Cancer. 2015 Feb 15;121(4):631-9. doi: 10.1002/cncr.29089. Epub 2014 Oct 24.

33.

A phase I study of temsirolimus and thoracic radiation in non--small-cell lung cancer.

Waqar SN, Robinson C, Bradley J, Goodgame B, Rooney M, Williams K, Gao F, Govindan R.

Clin Lung Cancer. 2014 Mar;15(2):119-23. doi: 10.1016/j.cllc.2013.11.007. Epub 2013 Nov 15.

34.

A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer.

Waqar SN, Gopalan PK, Williams K, Devarakonda S, Govindan R.

Chemotherapy. 2013;59(1):8-13. doi: 10.1159/000348584. Epub 2013 Apr 26.

PMID:
23635552
35.

Recent advances in lung cancer: summary of presentations from the 47 th annual meeting of the American Society of Clinical Oncology (ASCO) 2011.

Subramanian J, Waqar SN, Morgensztern D, Govindan R.

J Thorac Oncol. 2012 Jan;7(1):260-5. doi: 10.1097/JTO.0b013e31823a40a6.

36.

Targeted therapy in lung cancer: lessons learned from past experiences.

Subramanian J, Waqar SN, Govindan R.

J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1786-8. doi: 10.1097/01.JTO.0000407558.38416.c5. No abstract available.

37.

Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials.

Baggstrom MQ, Waqar SN, Sezhiyan AK, Gilstrap E, Gao F, Morgensztern D, Govindan R.

J Thorac Oncol. 2011 Jan;6(1):98-102. doi: 10.1097/JTO.0b013e3181fb50d8.

38.

Influenza vaccination in patients with cancer: an overview.

Boehmer LM, Waqar SN, Govindan R.

Oncology (Williston Park). 2010 Nov 15;24(12):1167-70. Review.

39.

Does malaria during pregnancy affect the newborn?

Yakoob MY, Zakaria A, Waqar SN, Zafar S, Wahla AS, Zaidi SK, Sarwari AR, Qureshi RN, Siddiqui AR.

J Pak Med Assoc. 2005 Dec;55(12):543-6.

40.

Myocardial ischaemia and reperfusion injury: reactive oxygen species and the role of neutrophil.

Saeed SA, Waqar MA, Zubairi AJ, Bhurgri H, Khan A, Gowani SA, Waqar SN, Choudhary MI, Jalil S, Zaidi AH, Ara I.

J Coll Physicians Surg Pak. 2005 Aug;15(8):507-14. Review.

PMID:
16202368
41.

Synergistic interaction of epinephrine and calcium ionophore in platelet aggregation.

Butt IF, Saeed SA, Waqar SN, Aslam M.

J Ayub Med Coll Abbottabad. 2005 Apr-Jun;17(2):1-5.

PMID:
16092638
42.

Cystic breast lymphangioma.

Waqar SN, Khan H, Mekan SF, Kayani N, Raja AJ.

J Pak Med Assoc. 2004 Oct;54(10):531-3. No abstract available. Erratum in: J Pak Med Assoc. 2005 Jan;55(1):50. Raja, AJ [added].

43.

Banti's syndrome: case report and review of literature.

Waqar SN, Jindani S, Baig NS, Waqar MA, Ismail FW, Tariq M.

J Pak Med Assoc. 2004 Feb;54(2):99-101. No abstract available.

44.

An enzymatic method for the detection of human serum albumin.

Javed MU, Waqar SN.

Exp Mol Med. 2001 Jun 30;33(2):103-5.

PMID:
11460880

Supplemental Content

Loading ...
Support Center